NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.346) was uploaded to the NHS England Website on Friday 7, February 2025.
The following changes have been introduced:
Selpercatinib (SEL1)
For the treatment of adults or adolescents aged 12 years and older with previously treated RET fusion positive non-medullary thyroid cancer where the following criteria have been met
Treatment criterion (#2) updated
Elacestrant monotherapy (ELAC1)
For the treatment of oestrogen receptor- positive, HER2-negative, locally advanced or metastatic breast cancer in patients previously treated with at least 12 calendar months of therapy with a CDK4/6 inhibitor-based combination where the following criteria have been met
Date moving into routine commissioning updated
Olaparib (OLAP10)
Olaparib as monotherapy for treatment of adults with deleterious or suspected deleterious germline BRCA1 or 2 mutations who have HER-2 negative locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane in the adjuvant/neoadjuvant/advanced disease settings and also treated with prior endocrine-based therapy if the patient has hormone-receptor positive disease where the following criteria have been met
Date moving into routine commissioning updated
Pembrolizumab (PEMB31)
Pembrolizumab monotherapy for adjuvant treatment after complete tumour resection in adult patients with UICC/AJCC 8th edition stage IIA or IIB or IIIA or N2 only IIIB non-small cell lung cancer and whose disease has not progressed on recently completed adjuvant platinum- based chemotherapy where the following criteria have been met
Date moving into routine commissioning updated